Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig
- 16 July 2005
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 48 (9), 1882-1890
- https://doi.org/10.1007/s00125-005-1847-7
Abstract
Aims/hypothesis The incretin hormone glucagon-like peptide 1 (GLP-1) has antihyperglycaemic effects, but its therapeutic usefulness is limited by its metabolic instability. Dipeptidyl peptidase IV (DPP-IV) is established as the primary inactivating enzyme, but the roles of other enzymes remain unclear. Methods The effect of candoxatril, a selective inhibitor of neutral endopeptidase (NEP) 24.11, on GLP-1 pharmacokinetics/pharmacodynamics with or without DPP-IV inhibition was examined in anaesthetised pigs. Results During GLP-1 infusion, candoxatril doubled C-terminal immunoreactivity, improving the pharmacokinetics (t ½ 2.3±0.1 to 8.8±1.2 min; metabolic clearance rate [MCR] 20.4±3.4 to 4.8±0.4 ml·kg−1· min−1; pt ½ 1.4±0.1 to 1.6±0.1 min; MCR 47.9±8.0 to 38.8±5.0 ml·kg−1·min−1). Insulin responses to intravenous glucose were unaffected by candoxatril, but glucose tolerance was improved (ΔAUCmin 27–87 118±5 to 74±14 min·mmol·l−1; glucose elimination rate [k] 6.6±0.5 to 8.6±0.5%; pt ½ 2.7±0.3 and 7.7±0.8 min; MCR 17.3±2.6 and 6.5±0.8 ml·kg−1·min−1 for valine pyrrolidide without and with candoxatril, respectively). However, intact GLP-1 pharmacokinetics were improved (t ½ 2.8±0.3 and 7.5±0.6 min; MCR 18.3±0.6 and 9.4±0.9 ml·kg−1·min−1; pmin 27– 87 103±8 to 62±14 min·mmol·l−1; k 6.8±0.4 to 11.4±1.4%; insulin ΔAUCmin 27–87 3,680±738 to 7,201±1,183 min·pmol·l−1; p<0.05). Conclusions/interpretation This study confirms a role for NEP-24.11 in GLP-1 metabolism in vivo, suggesting that up to 50% of GLP-1 entering the circulation may be degraded by NEP-24.11. Furthermore, combined inhibition of DPP-IV and NEP-24.11 is superior to DPP-IV inhibition alone in preserving intact GLP-1, which raises the possibility that the combination has therapeutic potential.Keywords
This publication has 45 references indexed in Scilit:
- Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?Expert Opinion on Investigational Drugs, 2004
- Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigsAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1Diabetes/Metabolism Research and Reviews, 2002
- Acute effect of the dual angiotensin‐converting enzyme and neutral endopeptidase 24‐11 inhibitor mixanpril on insulin sensitivity in obese Zucker ratBritish Journal of Pharmacology, 2001
- Formation and pharmacokinetics of the active drug candoxatrilat in mouse, rat, rabbit, dog and man following administration of the prodrug candoxatrilXenobiotica, 1997
- Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serumEuropean Journal of Biochemistry, 1993
- Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.JCI Insight, 1991
- UK-69, 578, a novel inhibitor of EC 3.4.24.11 which increases endogenous ANF levels and is natriuretic and diureticBiochemical and Biophysical Research Communications, 1989
- EFFECTS OF UK 69 578: A NOVEL ATRIOPEPTIDASE INHIBITORThe Lancet, 1989
- Structure-function relations in glucagon. Properties of highly purified Des-his1-, monoiodo-, and [Des-Asn28,Thr29](homoserine lactone27)-glucagonBiochemistry, 1975